Elizabeth Cairns is a Senior Biopharma Journalist at Informa. She specializes in covering themes related to medicine and healthcare, pharmaceuticals, and public health, with a focus on topics such as drugs and medication, pharmaceutical regulation, and patient care. Elizabeth's work has been featured in notable publications including Citeline and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Elizabeth Cairns' coverage primarily focuses on the healthcare and pharmaceutical industry, with a strong emphasis on biopharmaceuticals, clinical trials, drug development, and medical research. She frequently cites data and press releases in her articles.
If you are looking to reach out to Elizabeth Cairns for potential coverage or collaboration opportunities, consider offering access to exclusive data or insights related to breakthroughs in drug development or clinical trial results. Given her focus on scientific themes as well as private sector announcements, she might be interested in pitches that provide unique perspectives from key figures within pharmaceutical companies regarding new developments and trends shaping the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Back in March, Roche revealed that its breast cancer pill had failed in a pivotal Phase 3 trial. Data presented at ASCO reveal why.
By: Elizabeth Cairns
Roche's acmopatide cut A1C by 0.34% and reduced insulin use by 15% in a Phase 2 trial in type 1 diabetes patients with obesity.
By: Elizabeth Cairns
Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly successful product if they act synergistically.
By: Elizabeth Cairns
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
By: Elizabeth Cairns
Boehringer's survodutide showed 19% GI discontinuation rates in a Phase 3 obesity trial but was on par with Wegovy on weight loss.
By: Elizabeth Cairns
Novo Nordisk targets a ~2030 launch for UBT251, a triple-G obesity drug showing up to 19.7% weight loss in a China Phase 2.
By: Elizabeth Cairns
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Elizabeth Cairns
Less than two months after Belén Garijo took over as Sanofi's CEO, the drugmaker has found itself a new R&D chief.
By: Elizabeth Cairns
Senior biopharma journalist The failure of a Pfizer antibody-drug conjugate in its important late-stage lung cancer test is exactly what the New York drugmaker didn't need.
By: Elizabeth Cairns
Building on a pact from 2022, Eli Lilly has signed a new discovery collaboration with Abbisko Therapeutics that could see it pay the Chinese biotech up to $1.9 billion.
